Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the ...

A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...

Bristol Myers Squibb (BMY) closed at $48.02 in the latest trading session, marking a +2.85% move from the prior day.

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

American multinational biopharmaceutical firm Bristol Myers Squibb (BMS) has hosted a high-level professional forum in partnership with the U.S. Embassy in Hungary, titled “Innovating Together for ...

In a major setback to Zydus Lifesciences, the Delhi High Court has restrained the company from launching its proposed ...

U.S. health care companies are pouring unprecedented sums of money into lobbying efforts as they vie for influence with the Trump administration and the GOP congressional majority.

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

Indian generic drugs maker Dr Reddy's Laboratories posted a narrow miss of quarterly profit expectations on Wednesday, as it ...

Dispatch seeks to address two main challenges of immunotherapies in solid tumors: the lack of a target and the ...